Tabirafusp alfa tedromer

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Protein
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Protein
www.ebi.ac.uk
Drug name
Tabirafusp alfa tedromer
www.ebi.ac.uk

  • Human vascular endothelial growth factor receptor 1 (VEGFR-1) fragment containing immunoglobulin-like extracellular domain 2 (103-206, 1-104 in the current sequence) fused to a human vascular endothelial growth factor receptor 2 (VEGFR-2) fragment containing immunoglobulin-like extracellular domain 3 (208-308, 105-205 in the current sequence) fused via peptide linker GGGGSGGGGS (206-215) to the gamma 1 heavy chain of anti-[human interleukin 6 (IL-6)] (216-664) [VH (Homo sapiens IGHV3-23*03 -(IGHD) -IGHJ3*02, CDR-Kabat [5.17.10] (246-250.265-281.314-323)) (216-334) -Homo sapiens IGHG1*03v R431>K (CH1 (335-432), hinge (433-447), CH2 L451>A, L452>A, G454>A (448-557), CH3 L660>C (558-662), CHS (663-664)) (335-664)], (437-213')-disulfide with kappa light chain anti-[human interleukin 6 (IL-6)] (1'-213') [V-KAPPA (Homo sapiens IGKV1-13*02 -IGKJ1*01, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (443-443'':446-446'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, glycoform alfa substituted at an average of one sulfur atom of cysteine residues 660 and 660'' with (3RS)-1-[1,1,1-tris({3-[2-(2,2,2-tris{[(2-{α-(bromo/ethoxy/hydro/hydroxy)poly[1-(10,10-dimethyl-6-oxido-6-oxo-2,5,7-trioxa-10-aza-6λ5-phosphaundecan-10-ium-1-oyl)-1-methylethane-1,2-diyl]-ω-yl}-2-methylpropanoyl)oxy]methyl}ethoxy)acetamido]propanamido}methyl)-16,32-dioxo3,6,9,12,19,22,25,28-octaoxa-15,31-diazatetratriacontan-34-yl]-2,5-dioxopyrrolidin-3-yl (tedromer)
  • human vascular endothelial growth factor receptor 1 vegfr 1 fragment containing immunoglobulin like extracellular domain 2 103 206 1 104 in the current sequence fused to a human vascular endothelial growth factor receptor 2 vegfr 2 fragment containing immunoglobulin like extracellular domain 3 208 308 105 205 in the current sequence fused via peptide linker ggggsggggs 206 215 to the gamma 1 heavy chain of anti human interleukin 6 il 6 216 664 vh homo sapiens ighv3 23 03 ighd ighj3 02 cdr kabat 5 17 10 246 250 265 281 314 323 216 334 homo sapiens ighg1 03v r431 k ch1 335 432 hinge 433 447 ch2 l451 a l452 a g454 a 448 557 ch3 l660 c 558 662 chs 663 664 335 664 437 213 disulfide with kappa light chain anti human interleukin 6 il 6 1 213 v kappa homo sapiens igkv1 13 02 igkj1 01 cdr kabat 10 7 9 24 33 49 55 88 96 1 106 homo sapiens igkc 01 107 213 dimer 443 443 446 446 bisdisulfide produced in chinese hamster ovary cho cells cell line cho k1sv glycoform alfa substituted at an average of one sulfur atom of cysteine residues 660 and 660 with 3rs 1 1 1 1 tris 3 2 2 2 2 tris 2 α bromo ethoxy hydro hydroxy poly 1 10 10 dimethyl 6 oxido 6 oxo 2 5 7 trioxa 10 aza 6λ5 phosphaundecan 10 ium 1 oyl 1 methylethane 1 2 diyl ω yl 2 methylpropanoyl oxy methyl ethoxy acetamido propanamido methyl 16 32 dioxo3 6 9 12 19 22 25 28 octaoxa 15 31 diazatetratriacontan 34 yl 2 5 dioxopyrrolidin 3 yl tedromer
  • ksi 501
  • KSI-501
  • og 2072 tedromer
  • OG-2072 TEDROMER
  • og2072 tedromer
  • OG2072 TEDROMER
  • og2074
  • OG2074
  • tabirafusp alfa tedromer
  • Tabirafusp alfa tedromer
  • tabirafusp alfa tedromer [INN]
  • TABIRAFUSP ALFA TEDROMER [USAN]
  • tabirafusp alfa tedromer inn
  • tabirafusp alfa tedromer usan
  • tabirafusp alfa tedromere
  • Tabirafusp alfa tedromere
  • tabirafusp alfa tedromero
  • Tabirafusp alfa tedromero
  • Vascular endothelial growth factor receptor 1 (human extracellular immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor 2 (human extracellular immunoglobulin domain 3 fragment) fusion protein with peptide linker ((GGGGS)2) fusion protein with immunoglobulin G1 [236-alanine,237-alanine,239-alanine,445-cysteine] anti-(human interleukin 6) (human monoclonal OG2072 γ1-chain), disulfide with human monoclonal OG2072 κ-chain, dimer, 660-thioether with 1,1′-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6-diazahexadec-1-yl]-44-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-4,8,26,42-tetraoxo-2,13,16,19,22,29,32,35,38-nonaoxa-5,9,25,41-tetraazatetratetracont-1-yl]-2-[(2-bromo-2-methyl-1-oxopropoxy)methyl]-1,3-propanediyl] bis(2-bromo-2-methylpropanoate) core 9-arm star compd. with 4-hydroxy-N,N,N,10-tetramethyl-9-oxo-3,5,8-trioxa-4-phosphaundec-10-en-1-aminium inner salt 4-oxide homopolymer
  • vascular endothelial growth factor receptor 1 human extracellular immunoglobulin domain 2 fragment fusion protein with vascular endothelial growth factor receptor 2 human extracellular immunoglobulin domain 3 fragment fusion protein with peptide linker ggggs 2 fusion protein with immunoglobulin g1 236 alanine 237 alanine 239 alanine 445 cysteine anti human interleukin 6 human monoclonal og2072 γ1 chain disulfide with human monoclonal og2072 κ chain dimer 660 thioether with 1 1 2 11 11 bis 15 bromo 11 11 bis 2 bromo 2 methyl 1 oxopropoxy methyl 15 methyl 3 7 14 trioxo 9 13 dioxa 2 6 diazahexadec 1 yl 44 3 mercapto 2 5 dioxo 1 pyrrolidinyl 4 8 26 42 tetraoxo 2 13 16 19 22 29 32 35 38 nonaoxa 5 9 25 41 tetraazatetratetracont 1 yl 2 2 bromo 2 methyl 1 oxopropoxy methyl 1 3 propanediyl bis 2 bromo 2 methylpropanoate core 9 arm star compd with 4 hydroxy n n n 10 tetramethyl 9 oxo 3 5 8 trioxa 4 phosphaundec 10 en 1 aminium inner salt 4 oxide homopolymer

CAS registry numbers
  • 2839527-16-9
ChEMBL ID
CHEMBL6068304
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • Y44Q3G4CB6

First in class
No
Orphan designation
No

Drug name stem
-fusp; -mer

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    SDTGRPEVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKEPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLICEATVNGHLYKTNYLTHRQINTIIDVVLSPSHGIELSVGEKLVINCTARTELNVGIDENWEYPSSKHQHKKIVRDLKIQSGSEMKKELSTLTIDGVIRSDEGLYICHASSGLMIKKNSTEVRVHEKGGGGSGGGGSEVQLVESGGGLVQPGGSIRLSCAASGETESPEAMHWVRQAPGKGLEWVAKISPGGSWTYYSDTVTDRETESIDTSKSTAYLQMNSLRAEDTAVYYCARQAWGYYALDINGQGTINIVSSASTKGPSVEPLAPSSKSISGGTAALGCLVKDYFPEPVIVSWNSGALISGHTFPAVLQSSGLYSISSVVTVSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCKTHTCPPCPAPEAAGAPSVFLEPPKPKDTIMISRTPEVICVVVDVSHEDPEVKFNNYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWINGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLEPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWERGNVESCSVMHEALHNHYTQKSISESPGK
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQLTQSPSSLSASVGDRVTITCSASISVSYLYWYQQKPGKAPKLLIYDDSSLASGVISRESGSGSGIDETTISSLQPEDEATYYCQQWSGYPYTEGQGTKVEIKRIVAAPSVEIFPPSDEQLKSGTASVVCLINNEYPREAKVQWKVDNALQSGNSESTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC
  • Component
    Disulfide bridges
    Sequence
    23'-87' $ 23'''-87''' $ 30-79 $ 30''-79'' $ 123-185 $ 124''-185'' $ 133'-193' $ 133'''-193''' $ 237-311 $ 237''-311'' $ 361-417 $ 361''-417'' $ 437-213' $ 437''-437''' $ 443-4343'' $ 446-446'' $ 478-538 $ 478''-538'' $ 584-642 $ 584''-642''
  • Component
    Glycosylation sites (N)
    Sequence
    36 $ 36'' $ 68 $ 68'' $ 123 $ 123'' $ 196 $ 196'' $ 514 $ 514''

Related records

Trials (2)